Abbott Laboratories completed its acquisition of Exact Sciences, a cancer diagnostics company, in a deal valued at approximately $23 billion. This acquisition expanded Abbott's presence in cancer diagnostics and integrated Exact Sciences' products, including the Cologuard colorectal cancer screening test, into Abbott's healthcare portfolio. In 2025, Abbott's Medical Devices business unit achieved over 10% year-on-year revenue growth, driven by rising demand for connected health devices. Abbott's diabetes care portfolio generated nearly $8 billion in revenue in FY2025, reflecting a 17.5% increase from FY2024. Additionally, Abbott reported full-year 2025 net sales of $44.328 billion, up 5.7% from $41.95 billion in 2024, supported by strong growth in Medical Devices and Established Pharmaceuticals. In the first quarter of 2026, Abbott's net sales rose 7.8% year over year to $11.164 billion, indicating continued growth despite challenges in other segments.